PeptideStack
5.2kquestions
20kanswers
220users

Is PIONEER-1 a fair comparison of tirzepatide against its comparator arm?

Asked 28 Jul 2024Modified 2.0 years agoViewed 11k times
29

The case in front of me: PIONEER-1 · tirzepatide.

The claim is plausible, which is exactly why I want to check it.

I am able to read a paper if someone points me at one.

Is there data behind this, or is it received wisdom?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questionsoral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

14 questions
shareeditfollowflag
VR
askedvalentina_rossi16k2828 Jul 2024
4This is the first explanation of that which has actually made sense to me. – assay_blank 5 months ago
5Note that the label instructions differ between agents on precisely this point. – sian_llewellyn 7 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 11k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.